These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38960658)

  • 1. [Advances in the treatment of thrombotic thrombocytopenic purpura].
    Uchihara M; Kubo M; Matsumoto M
    Rinsho Ketsueki; 2024; 65(6):567-575. PubMed ID: 38960658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Novel treatment strategies for acquired thrombotic thrombocytopenic purpura].
    Matsumoto M
    Rinsho Ketsueki; 2023; 64(9):1124-1130. PubMed ID: 37899191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombotic thrombocytopenic purpura.
    Joly BS; Coppo P; Veyradier A
    Blood; 2017 May; 129(21):2836-2846. PubMed ID: 28416507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathogenesis and novel treatment of thrombotic thrombocytopenic purpura].
    Matsumoto M
    Rinsho Ketsueki; 2021; 62(5):480-485. PubMed ID: 34248125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
    Scully M; Cataland SR; Peyvandi F; Coppo P; Knöbl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Callewaert F; Biswas D; De Winter H; Zeldin RK;
    N Engl J Med; 2019 Jan; 380(4):335-346. PubMed ID: 30625070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caplacizumab for relapsing thrombotic thrombocytopenic purpura.
    Kaczmarek V; Holle J; Astudillo R; Kempf C; Bufler P; Müller D
    Pediatr Nephrol; 2019 Sep; 34(9):1625-1628. PubMed ID: 31177334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment strategy for patients with thrombotic thrombocytopenic purpura].
    Yagi H
    Rinsho Ketsueki; 2021; 62(8):1222-1228. PubMed ID: 34497210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023.
    Matsumoto M; Miyakawa Y; Kokame K; Ueda Y; Wada H; Higasa S; Yagi H; Ogawa Y; Sakai K; Miyata T; Morishita E; Fujimura Y;
    Int J Hematol; 2023 Nov; 118(5):529-546. PubMed ID: 37689812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura.
    Dane K; Chaturvedi S
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):539-547. PubMed ID: 30504355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura.
    Kubo M; Matsumoto M
    Int J Hematol; 2023 Mar; 117(3):331-340. PubMed ID: 36757521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura.
    Gómez-Seguí I; Fernández-Zarzoso M; de la Rubia J
    Expert Rev Hematol; 2020 Nov; 13(11):1153-1164. PubMed ID: 32876503
    [No Abstract]   [Full Text] [Related]  

  • 12. Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children.
    Siddiqui A; Journeycake JM; Borogovac A; George JN
    Pediatr Blood Cancer; 2021 May; 68(5):e28949. PubMed ID: 33660913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refining the standard of care in immune thrombotic thrombocytopenic purpura.
    Laurence J
    Clin Adv Hematol Oncol; 2024 Oct; 22(8):381-391. PubMed ID: 39356816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel mechanisms of action of emerging therapies of hereditary thrombotic thrombocytopenic purpura.
    Zheng XL
    Expert Rev Hematol; 2024 Jul; 17(7):341-351. PubMed ID: 38752747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When targeted therapies alleviate the burden of TPE: The example of immune-mediated TTP.
    Picod A; Coppo P
    Transfus Apher Sci; 2019 Jun; 58(3):273-277. PubMed ID: 31018909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombotic Thrombocytopenic Purpura: Beyond Empiricism and Plasma Exchange.
    Tsai HM
    Am J Med; 2019 Sep; 132(9):1032-1037. PubMed ID: 30928346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis and treatment of thrombotic thrombocytopenic purpura].
    Kubo M; Matsumoto M
    Rinsho Ketsueki; 2020; 61(5):529-535. PubMed ID: 32507820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. True vs. false immune-mediated thrombotic thrombocytopenic purpura exacerbations: a clinical case in the caplacizumab era.
    Laganà A; Trisolini SM; Maglione R; Mahnaz SB; Imperatore S; Vitullo D; Capria S
    Blood Coagul Fibrinolysis; 2024 Jan; 35(1):37-42. PubMed ID: 37994623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic plasma exchange in thrombotic thrombocytopenic purpura.
    Picod A; Provôt F; Coppo P
    Presse Med; 2019 Nov; 48(11 Pt 2):319-327. PubMed ID: 31759790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.
    Furlan M; Robles R; Solenthaler M; Lämmle B
    Blood; 1998 Apr; 91(8):2839-46. PubMed ID: 9531594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.